NeurAxon Announces Presentations at the 2011 BIO International Convention and the World Drug Targets Summit

WALTHAM, Mass.--(BUSINESS WIRE)-- NeurAxon, Inc. today announced that Lawrence Bloch, M.D., J.D., CEO of NeurAxon, will present at the 2011 BIO International Convention on June 28th, and John Andrews, Ph.D., Chief Scientific Officer of NeurAxon, will participate in a panel at the World Drug Targets Summit on July 21st.

Dr. Bloch’s presentation at the BIO International Convention will be given Tuesday, June 28, 2011 at 2pm Eastern Time in the Business Forum at the Walter E. Washington Convention Center in Washington DC. Dr. Bloch will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including NXN-188, an oral, first-in-class selective nNOS inhibitor and 5HT agonist and NXN-462, an oral selective nNOS inhibitor. Both candidates are currently in human clinical trials.

Dr. Andrews will participate in a panel at the World Drug Targets Summit entitled “Undruggable vs. High Hanging Fruit in Drug Discovery” taking place Thursday, July 21, 2011 at 3pm Eastern Time at the Sheraton Commander Hotel in Cambridge, MA.

About NeurAxon, Inc.

NeurAxon, Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.



CONTACT:

MacDougall Biomedical Communications
Chris Erdman, 781-235-3060

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics’ CEO Aron Knickerbocker is exiting the company.

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…